Autoimmune diseases: targets, biology, and drug discovery
文献类型：期刊论文
| 作者 | Li, Shu-jie4,5; Wu, Yan-li5; Chen, Juan-hua5; Shen, Shi-yi3,5; Duan, Jia2,3,5; Xu, H. Eric1,5
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2023-12-14 |
| 页码 | 12 |
| ISSN号 | 1671-4083 |
| 关键词 | autoimmune disease autoantigen immunotherapy type 1 diabetes insulin drug discovery |
| DOI | 10.1038/s41401-023-01207-2 |
| 通讯作者 | Li, Shu-jie(lishujie@simm.ac.cn) ; Duan, Jia(duanjia@simm.ac.cn) ; Xu, H. Eric(Eric.Xu@simm.ac.cn) |
| 英文摘要 | Autoimmune diseases (AIDs) arise from a breakdown in immunological self-tolerance, wherein the adaptive immune system mistakenly attacks healthy cells, tissues and organs. AIDs impose excessive treatment costs and currently rely on non-specific and universal immunosuppression, which only offer symptomatic relief without addressing the underlying causes. AIDs are driven by autoantigens, targeting the autoantigens holds great promise in transforming the treatment of these diseases. To achieve this goal, a comprehensive understanding of the pathogenic mechanisms underlying different AIDs and the identification of specific autoantigens are critical. In this review, we categorize AIDs based on their underlying causes and compile information on autoantigens implicated in each disease, providing a roadmap for the development of novel immunotherapy regimens. We will focus on type 1 diabetes (T1D), which is an autoimmune disease characterized by irreversible destruction of insulin-producing beta cells in the Langerhans islets of the pancreas. We will discuss insulin as possible autoantigen of T1D and its role in T1D pathogenesis. Finally, we will review current treatments of TID and propose a potentially effective immunotherapy targeting autoantigens. |
| WOS关键词 | VON-WILLEBRAND-FACTOR ; CD4 T-CELLS ; RECENT-ONSET ; TYPE-1 ; AUTOANTIBODIES ; AUTOANTIGEN ; INSULIN ; MANAGEMENT ; EPITOPE ; IDENTIFICATION |
| 资助项目 | CAS Strategic Priority Research Program[XDB37030103] ; Shanghai Municipal Science and Technology Major Project[2019SHZDZX02] ; Shanghai Municipal Science and Technology Major Project (HEX) ; National Natural Science Foundation of China[32130022] ; National Natural Science Foundation of China[82121005] ; Lingang Laboratory Grant[LG-GG-202204-01] ; National Key R&D Program of China[2018YFA0507002] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | NATURE PUBL GROUP |
| WOS记录号 | WOS:001126246000002 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/308347]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Li, Shu-jie; Duan, Jia; Xu, H. Eric |
| 作者单位 | 1.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China 2.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 4.Fujian Med Univ Union Hosp, Dept Tradit Chinese Med, Fuzhou 350000, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Shu-jie,Wu, Yan-li,Chen, Juan-hua,et al. Autoimmune diseases: targets, biology, and drug discovery[J]. ACTA PHARMACOLOGICA SINICA,2023:12. |
| APA | Li, Shu-jie,Wu, Yan-li,Chen, Juan-hua,Shen, Shi-yi,Duan, Jia,&Xu, H. Eric.(2023).Autoimmune diseases: targets, biology, and drug discovery.ACTA PHARMACOLOGICA SINICA,12. |
| MLA | Li, Shu-jie,et al."Autoimmune diseases: targets, biology, and drug discovery".ACTA PHARMACOLOGICA SINICA (2023):12. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。